EIF2AK3 and breast carcinoma: The clinical impact of PERK as a molecular target for overcoming chemoresistance to epirubicin- or tamoxifen-based regimens for treating patients with breast cancer has been previously evaluated; GSK2606414, a PERK inhibitor, was shown to sensitize MCF-7 breast cancer cells to epirubicin and tamoxifen [47].